Croma-Pharma Presents juvenus, a New Polynucleotide Based Injectable for Skin Hydration and Tissue Elasticity Restoration
13.9.2021 16:00:00 EEST | Business Wire | Press release
Croma-Pharma (Croma) today announced the addition of juvenus to its product portfolio. It is an injectable, elastic, colourless and reabsorbable gel, based on polymerized polynucleotides (PDRN)1,2 of natural origin, which hydrates the skin and restores tissue elasticity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210913005466/en/
Croma-Pharma Presents juvenus, a New Polynucleotide Based Injectable for Skin Hydration and Tissue Elasticity Restoration (Photo: Business Wire)
juvenus is produced by a European certified manufacturer and distributed by Croma. In a first phase Croma will market the product within its network of affiliated sales companies (AT, FR, DE, NL, PL, PT, RO, ES, CH, UK, IT), followed by other European markets via independent distribution partners.3
Innovative mode of action to fight signs of skin aging
Thanks to its biochemical properties, juvenus improves skin elasticity and is effective against various signs of aging, such as wrinkles, loss of skin firmness or skin tone. The elastic and injectable gel is based on polymerized polynucleotides (PDRN), showing several positive effects on the skin:
- Antioxidative effect: The enzyme-related degradation of polynucleotide molecules can lead to an amplification of protective activities against free radicals. 4
- Moisturization: The hydrophilic and polyanionic structure enables PDRN to bind water molecules, resulting in an intensive moisturization of the tissue.
- Creation of an optimal environment for fibroblast growth: Extensive moisturization and the antioxidative activity contribute to the creation of an optimal physiological environment for the growth of the fibroblasts favoring the restoration of the tissue elasticity.5
Two concentrations for different types of skin blemishes
juvenus is available in two concentrations and suitable for all skin types and age groups:
- juvenus 2%, medium: slightly deeper wrinkles, such as superficial perioral wrinkles, cheek wrinkles, medium scars
- juvenus 2,5%, strong: medium-deep wrinkles and larger areas of the body, such as neck, back of the hands, abdomen, cleavage, thighs and glutes, nasogenien wrinkles, deep/large scars
Broad range of indications for facial and body treatments with a proven safety profile
The application range of juvenus is extensive and stretches from the treatment of slightly deeper facial wrinkles to the treatment of larger areas of the body.
juvenus shows a proven safety profile due to the PDRN extraction and purification at high temperature – a procedure that allows to recover an over 95% pure active substance with inactivated proteins and peptides. The latter guarantees the safety of the product and the lack of immunological side effects.
"Croma always strives to bring exceptional products to the market that meet the growing demands of our customers. With juvenus, we can offer a new and safe injectable with an innovative mode of action that targets the signs of skin aging," comments Managing Director Andreas Prinz.
About Croma
Founded in 1976, Croma-Pharma GmbH (Croma) is an Austrian family-owned company that specializes in the industrial production of hyaluronic acid syringes for the fields of medical aesthetics, ophthalmology and orthopaedics. Croma currently runs 12 international sales companies and distributes its products in more than 70 countries. Within its global sales network, Croma focuses with own branded products on minimally invasive aesthetic medicine. Besides a broad range of HA fillers from the own production site, Croma markets PDO lifting threads, a Platelet Rich Plasma (PRP) system and high quality skincare technologies in its core strategic markets.
The medical practitioner confirms having informed the patient of a likely risk associated with the use of the medical device in line with its intended use. For risks and adverse events associated with the use of the product consult the instructions of use.
1 Müller Esterl, Biochemie. 1. Auflage 2004, Elsevier
2 Squadrito F, Bitto A, Irrera N, Pizzino G, Pallio G, Minutoli L and Altavilla D (2017) Pharmacological Activity and Clinical Use of PDRN. Front. Pharmacol. 8:224. doi: 10.3389/fphar.2017.00224
3 available with CE 0373
4 Cavallini M, Papagni M. Long chain polynucleotides gel and skin biorevitalization. Int J Plast Dermatol 2007; 3: 27-32.
5 Pak CS, Lee J, Lee H, et al. A phase III, randomized, double-blind, matched-pairs, active-controlled clinical trial and preclinical animal study to compare the durability, efficacy and safety between polynucleotide filler and hyaluronic acid filler in the correction of crow’s feet: a new concept of regenerative filler. J Korean Med Sci 2014: 29: 201– 209.
PRJ0821
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210913005466/en/
Contact information
CROMA-PHARMA GmbH
Stefanie Höhn
Global Director Communications
Tel.: +43 676 846868 190
Mail: stefanie.hoehn@croma.at
Web: www.croma.at
CROMA-PHARMA GmbH
Simone Turek
External Communications Manager
Tel.: +43 676 846868 654
Mail: simone.turek@croma.at
Web: www.croma.at
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting20.3.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver. “At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.” Details on key data presentations at AAD include: Late-Breaking Oral Presentations Hidradenitis Suppurativa Povorcitinib in Patients With Moderate to Severe Hidradenitis Suppurativa: 54-Week Efficacy and Safety Results From the STOP-HS1 & STOP-HS2 Phase 3 Studies (Session: S034 – Late-Breaking Research: Sess
MUSASHI JAPAN by TAIMATSU Launches “Road to Shogun” – A Journey Through Craftsmanship and Discovery20.3.2026 14:58:00 EET | Press release
Musashi Japan by TAIMATSU Co., Ltd., a contemporary Japanese knife brand rooted in the spirit of craftsmanship and cultural harmony, has announced its newest experiential campaign: “Road to Shogun.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320887471/en/ Designed as the brand’s most ambitious customer journey to date, the campaign invites visitors to explore participating Musashi Japan stores while discovering the traditions, culture and craftsmanship that inspire the brand. Inspired by the journey towards mastery, the experience encourages participants to progress through a series of ranks whilst visiting stores and unlocking rewards that celebrate elements of everyday Japanese culture. At Musashi Japan, craftsmanship is not only about the final product, but also about the path taken to achieve mastery. The Road to Shogun reflects this philosophy by guiding customers through a journey that mirrors the dedication, cu
Futur Delivers Strong Growth and Record Profit in 202520.3.2026 13:05:00 EET | Press release
"2025 was a record year for Futur. In a market characterized by sharp market fluctuations, Futur continued to invest, grow and deliver strong results. Behind this record performance is stable customer growth, strong inflows and cost discipline. Our close cooperation with over 60 partners gives customers the freedom to choose the asset management and advisory services that best suit them. The strategy of letting the customer choose is appreciated, which is reflected in us welcoming more than 21,000 new customers during the year", says Torgny Johansson, CEO of Futur. "We are optimistic about the future. Futur has great opportunities to continue growing in the coming years by developing innovative and efficient services for savings and pensions. I am proud of how all employees have purposefully embraced our strategy and continue to work towards the goal of reaching 500 billion kronor in savings capital with the current organization", concludes Torgny Johansson, CEO of Futur. Key highlight
Lyten to Establish a Lyten Industrial Hub in Poland20.3.2026 13:00:00 EET | Press release
Lyten, the supermaterial applications company and global leader in an energy storage, has announced its interest in establishing a Lyten Industrial Hub in Poland. In 2026, Lyten will conduct a feasibility study to assess manufacturing requirements for Lyten products, potential private and public partnerships, and the necessary energy and utility infrastructure. The industrial hub will be built around Lyten Dwa – the energy storage production plant and R&D center in Gdańsk. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320045026/en/ Lyten Voltpack Mobile System in front of Lyten Dwa plant in Gdansk, Poland In February 2026, Lyten announced the establishment of its first Industrial Hub in Skellefteå, Sweden, on the site of the former Northvolt Ett plant, which it recently acquired. It will combine battery production with a data center with a capacity of up to 1 GW, being built by EdgeConneX. Once it reaches full production
PUMA Reveals Its Most Powerful International Football Kit Lineup yet on the Streets of New York City20.3.2026 09:00:00 EET | Press release
Global sports company PUMA unveiled its new national team kits for 11 nations with a street-level event at Domino Square in New York City, that placed football, music, food, and culture at the center stage in a celebration of the game. Rather than launching in a stadium setting or in a cinematic brand film, PUMA chose to reveal the kits in play, worn first by local community players from each nation on the streets of New York. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320641449/en/ Reinforcing its status as a leading force in football kits at this summer’s competition, PUMA unveiled jerseys for 11 nations, including the most prominent African partner federations of any brand in the tournament, in a community-first celebration of football, music, and culture in New York City. Four continents are united under 11 nations: Portugal, Morocco, Ghana, Paraguay, Senegal, Côte d’Ivoire, Czech Republic, Switzerland, New Zealan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom